(Q38558943)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Expanding the therapeutic spectrum of metformin: from diabetes to cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

F Coperchini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

P Leporati

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

L Chiovato

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

2 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1047-1055

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233338%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40618-015-0370-z

20 February 2020

exact match

0 references

cites work

Metformin: its botanical background

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Risk of cancer in diabetes: the effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

21 January 2018

The "slower" the better.

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Nonalcoholic fatty liver disease and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Does use of metformin protect against cancer in Type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

AMPK: a nutrient and energy sensor that maintains energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

AMPK activation inhibits the expression of HIF-1alpha induced by insulin and IGF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Targeting the mTOR signaling network in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

An energetic tale of AMPK-independent effects of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

NF-kappaB in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

NF-κB control of T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin induces apoptosis of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

New perspective for an old antidiabetic drug: metformin as anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The effect of metformin on apoptosis in a breast cancer presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The effect of metformin on breast cancer outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and the risk of endometrial cancer: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Association between diabetes, diabetes treatment and risk of developing endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin use and lung cancer risk in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and breast and gynecological cancer risk among women with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and cancer: mounting evidence against an association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

The morphological and molecular features of the epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-015-0370-Z

Thyreotropin levels in diabetic patients on metformin treatment

21 January 2018

1 reference

12 December 2020

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

1 reference

12 December 2020

Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.

1 reference

12 December 2020

Antiproliferative action of metformin in human lung cancer cell lines

1 reference

12 December 2020

The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus

1 reference

12 December 2020

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study

1 reference

12 December 2020

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

1 reference

12 December 2020

Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes

1 reference

12 December 2020

Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo

1 reference

12 December 2020

1 reference

12 December 2020

Glioblastoma stem cells: a new target for metformin and arsenic trioxide.

1 reference

12 December 2020

Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.

1 reference

12 December 2020